Bladder Cancer Briefs June 7, 2023

Read prior editions

What is Carcinoma In-Situ (CIS)?

Carcinoma in situ (CIS), also known as urothelial carcinoma in situ, is a subtype of non-muscle invasive bladder cancer. It is characterized by the presence of abnormal cancer cells confined to the innermost layer (urothelium) of the bladder lining. Unlike other forms of non-muscle invasive bladder cancer (NMIBC), sometimes, CIS does not present as visible tumors within the bladder.

Urologist Dr. Peter Black from the Vancouver General Hospital in Canada and pathologist Dr. Hikmat Al-Ahmadie from Memorial Sloan Kettering Cancer Center in New York City shared their expertise on carcinoma in situ (CIS) during a fascinating 2022 webinar. They shed light on what CIS is and treatments that patients can consider.

We invite you to watch the webinar by clicking on the button below.

Resources for Patients and Families

Have you checked out BCAN’s glossary of commonly used terms associated with bladder cancer? It’s a valuable resource that can help you, your friends, or family better understand the journey of bladder cancer.